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It is well accepted at present that the majority of antibodies in human serum 
are  produced  as a  result  of natural  immunization.  However,  the  information 
about the  nature and specificity of natural  IgG antibodies is  relatively scarce. 
The classical natural antibodies against blood group antigens, which display a 
well-defined anti-carbohydrate specificity, are mostly of the  IgM class and are 
present in only part of the population, according to the blood type (1,  2).  The 
anti-T or anti-Thomsen Friedenreich antibodies, which interact with/3-galactosyl 
groups usually penultimate to terminal sialic acid residues on various cell mem- 
branes, are similarly mostly of the IgM class (3, 4). In a recent study, Guilbert et 
al. (5) demonstrated, in pooled human sera, low activity of natural IgG antibodies 
to a  variety of evolutionary preserved proteins such as thyroglobulin, actin, or 
myoglobin. Although some cross-reactivity was noted, these antibodies could be 
inhibited  mainly  by  their  respective  antigens.  The  structure  of the  epitopes 
involved could not be determined. 
In  the  present  study we report  on the identification and isolation of a  new 
natural IgG antibody with a  distinct anti-a-galactosyl reactivity. The anti-galac- 
tosyl (anti-Gal) 1 antibody was found to be of interest for the following reasons: 
(a) The anti-Gal is the only natural IgG antibody found to be present in high 
titers in the serum of every normal individual. (b) The anti-Gal seems to display 
a  physiological role in senescence of human erythrocytes (RBC). The anti-Gal- 
binding site  on  the  human  RBC  differs from any known galactose-containing 
RBC antigen, and possibly is an epitope on membranal glycolipids. (c) Since anti- 
Gal is constantly produced  throughout life, the determination of its titer  may 
serve as a potential tool for the assessment of the humoral immune response in 
individual patients. 
Materials and Methods 
RBC and Sera.  Whole blood was obtained from normal donors and from 13  + thalassemie 
patients, using sodium citrate or heparin as anticoagulant. Sera were obtained from clotted 
blood of normal  individuals. All blood  samples  studied were  screened  for ABO  (H) 
specificities by regular blood banking methods. 
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Isolation of Anti-Gal  IgG from Normal  Serum.  The natural anti-Gal IgG was isolated 
from heat-inactivated sera of normal individuals of AB blood group by affinity chroma- 
tography, using as immunoadsorbent melibiose-Sepharose (Sigma Chemical Co., St. Louis, 
MO),  expressing  terminal  a-galactosyl residues.  Sera  samples were applied  in  100-ml 
batches onto a  10-ml melibiose-Sepharose column at 37 °C at a flow rate of 10 ml/h. The 
unbound serum proteins were eluted with 200 ml phosphate-buffered saline (PBS).  The 
bound  antibody was eluted  by 20  ml of 0.5  M  l>-galactose  and passed through  a  5-ml 
column of protein A-Sepharose (Sigma Chemical Co.). This second column, which binds 
the  IgG molecules complexed with galactose eluted  from the affinity chromatography 
column, was washed with 500 ml PBS. The IgG was eluted with 7 ml of 0.1  M glycine 
HCI buffer, pH 2.6 and immediately neutralized with an equal volume of Tris-HCi buffer, 
pH 8.4.  The eluate was dialyzed against two changes of PBS.  To remove any possible 
residual  anti-T  (Thomsen  Friedenreich)  antibody  activity,  the  dialyzed  eluates  were 
absorbed on Vibrio cholera neuraminidase (VCN)-treated human RBC at a  3:1  ratio (3). 
For  this  purpose  10  ml  of  10%  0  type  RBC  were  incubated  with  0.1  U/ml  VCN 
(Behringwerke, Federal Republic of Germany) for 30 min at 37°C in PBS containing 3 
mM CaCI2. The absorption was confirmed by demonstrating complete lack of IgG binding 
to VCN-treated human RBC. The anti-Gal reactivity was assessed by the binding of the 
antibody to the  terminal  a-galactosyl groups on  rabbit  RBC  (RabRBC)  glycolipids (6) 
followed by agglutination or rosetting antiglobulin test with K562 cells (7).  The anti-a- 
galactosyl  specificity of the  antibody  was  determined  by  inhibition  experiments  with 
various carbohydrates (Sigma Chemical Co.). 
Hemagglutination  Assay and Inhibition  by Carbohydrates.  Hemagglutination activity of 
the isolated anti-Gal was titrated by mixing twofold serial dilutions of the antibody sample 
with an equal volume of 0.5%  RabRBC suspension in the wells of microtiter tray. The 
diluent was PBS, pH 7.4. Agglutination was evaluated after the RBC were settled at room 
temperature for 2 h. Titers were expressed as the greatest dilution of sample that caused 
complete agglutination. 
To assess the capacity of a given carbohydrate to inhibit hemagglutination, the antibody 
at  a  titer  of  two  agglutinating  units  was  mixed  with  various  concentrations  of the 
carbohydrate in an iso-osmotic solution in titration wells. After 30-min incubation of the 
mixture at 37 °C, the 0.5%  RabRBC suspension was added and scored for agglutination 
as described above. 
EA Rosetting Direct Antiglobulin  Test (DAT) with K562 Cells.  The test is based on the 
high affinity between the Fc portion of RBC-bound IgG molecules and the Fc receptors 
on the myeloid cell line  K562.  This interaction leads to the formation of erythrocyte- 
antibody (EA) rosettes. The proportion of the K562 cells forming EA rosettes is related 
to the amount of the  RBC-bound antibody molecules (8).  A  quantity of 0.1  ml of 1% 
suspension  of washed  RBC  was  mixed  with  an  equal  volume  of antibody-containing 
solution and incubated for 30 min at 37 ° C. Thereafter, the RBC were washed twice and 
resuspended in 0.1  ml of rabbit anti-human serum (broad spectrum containing anti-human 
IgG, IgM, IgA, and anti-complement; Ortho Diagnostics, Raritan,  NJ) or, if stated,  in 
specific rabbit anti-human IgG serum (Ortho). The suspension was incubated for 30 min 
at 24°C. Thereafter, the RBC were washed twice, mixed with 0.1  ml K562 cell suspension 
in PBS (106 cells/ml), spun for 5 min at 200 g, and incubated for 30 min at 4°C.  The 
pellet was resuspended and the percentage of K562 cells binding the IgG-coated RBC 
and forming EA rosettes was scored in a hemocytometer. This antiglobulin test was found 
to be 20-40-fold  more sensitive than  the regular antiglobulin  test and highly specific, 
since  RBC  lacking bound  Ig formed no rosettes with  K562 cells (8).  Inhibition of the 
rosetting antiglobulin test by various carbohydrates was performed by their addition to 
the antibody solution before the incubation with RBC as described above. 
Sensitization of Staphylococcus aureus (Staph A) Bacteria with Anti-Gal.  Staph  A  strain 
Cowan  1, containing protein A and prefixed with 0.1% glutaraldehyde, were incubated 
with the purified anti-Gal at a  5% final concentration of the bacteria, for 24 h  at 4°C. 
The sensitized  bacteria  were  washed and  tested  for binding  to  galactosyl residues  on 
RabRBC by mixed hemagglutination.  Staph A sensitized with anti-Gal agglutinated  1% GALILI ET  AL.  1521 
RabRBC at a  concentration of bacteria as low as 0.01%.  For visualization of anti-Gal 
binding to various RBC populations, 1% RBC suspensions were mixed with 1% sensitized 
Staph A, spun for 5 min at 400 g, and incubated for 1 h at room temperature. Thereafter, 
the pellets were gently resuspended and fixed with 0.1% glutaraldehyde. These samples 
were  processed  for  scanning electron  microscopy according to  procedure  previously 
described (9). 
Separation of RBC Age-related Subpopulations.  Senescent and young normal RBC were 
separated on the basis of age-dependent differences in density, on a discontinuous Percoll 
gradient (Pharmacia Fine Chemicals, Piscataway, N  J) according to the method of Alder- 
man et al. (10). The subpopulation of senescent RBC with density of >1.11  g/ml (1-2% 
of total RBC) and the subpopulation of young RBC with density of <1.08 g/mi (1-2% of 
total RBC) were isolated, washed twice in PBS, and used for further analysis. 
Enzymatic Treatment of HuRBC.  The  interaction of the anti-Gal with HuRBC was 
assessed after treatment with the following enzymes: (a) Pronase (from Streptomyces  griseus; 
Sigma Chemical Co.): HuRBC were brought to a 10% suspension in PBS containing 0.1% 
pronase and incubated for  1 h at 37°C.  Thereafter; the RBC were washed twice and 
adjusted to 10% concentration in PBS for further studies. (b) a-Galactosidase (from coffee 
beans; Sigma Chemical Co.): pronase-treated RBC were suspended in 0.1  M citric acid, 
0.2 M Na2HPO~ buffer, pH 5.0 containing 3% glycerol, to a concentration of 10%. a- 
Galactosidase was added to a final concentration of 5 U/ml. The suspension was incubated 
for 3 h at 37°C and washed, thereafter, twice with PBS. Reactivity of the enzyme was 
confirmed by parallel elimination of the agglutinability of B-type RBC by anti-B antibodies 
(1,  2). (c)/3-Galactosidase  (from E. coli; Sigma Chemical Co.):  the pronase-treated RBC 
were resuspended in 0.01  M Tris HCI buffer containing 0.01  MgCI2, 0.01  M mercapto- 
ethanol, and 0.1  M NaCI, pH 7.5. 500 U of 3-galactosidase were added to the 1-ml RBC 
suspension. The mixed suspension was incubated for 3 h at 37 °C and washed twice with 
PBS.  Reactivity of the enzyme was confirmed by the hydrolysis of 0-nitrophenyl 3-D- 
galactoside to 0-nitrophenol and galactose. 
Results 
Characteristics  and  Specificity of the Anti-Gal Isolated  by Affinity  Chromatogra- 
phy.  The  normal  AB  sera  contained  anti-Gal  reactivity at  titers  of  1:800  to 
1:1,600  (Table  I),  as  assessed  by  the  binding  to  RabRBC  in  the  rosetting 
antiglobulin  test.  Due  to  its  IgG  nature,  the  unseparated  anti-Gal  failed  to 
agglutinate  other  RabRBC  in  the  presence  of the  whole  serum  IgG.  After 
fractionation  of  100-ml  AB  serum  samples  on  a  10-ml  melibiose-Sepharose 
column,  the  anti-Gal  titer  decreased  in  the  effluent  from  1:800  to  1:200, 
suggesting that  70-80%  of the antibody activity was retained  on the column. 
The specificity of the column absorbing the antibody was demonstrated by the 
finding that anti-Rh titer in one of the sera tested was not altered after fraction- 
tion (Table I). The antibody obtained after specific elution with 0.5 M galactose, 
passage through the protein A  column, and adsorption on VCN-treated  RBC, 
was found to produce 100% rosettes with RabRBC at a titer of 1:500 decreasing 
to 10% rosettes at the endpoint ranging between  1:1600 and 1:6400.  The anti- 
galactosyl specificity of the antibody is described below (Table II). The antibody 
preparation  directly agglutinated RabRBC at titers ranging between  1:64  and 
1:256,  depending on  the donor of the AB  serum.  Sepharose column without 
melibiose did not bind antibody. 
The  IgG  nature  of the  antibody obtained after  the  protein  A  column  was 
further confirmed by the single identical precipitin line obtained in Ouchterlony 
double immunodiffusion assay against broad spectrum rabbit anti-human Ig and 1522  NATURAL  ANTIGALACTOSYL  IgG  IN  HUMAN  SERUM 
TABLE  I 
Anti-Gal Reactivity in AB Sera and in Eluates After Affinity Chromatography 
Assay for antibody reactivity 
Antibody source  Rosetting antiglobu-  Hemagglutina-  Rosetting anti- 
tion with  globulin test 
lin test with RabRBC  RabRBC  with Rh  ÷ RBC 
AB serum 
Effluent AB serum from melibiose- 
Sepharose column 
Anti-Gal eluted from melibiose-Sepha- 
rose column 
Effluent AB serum from Sepharose col- 
umn 
1:800 to 1:1,600*  ND  1:400  * 
1:200 to 1:400  ND  1:400  * 
1:1,600 to  1:6,400  1:64 to 1:256  No reactivity 
1:800 to 1:1,600  ND  ND 
ND, not done. 
* Endpoint of rosetting antiglobulin test defined as the antibody titer yielding >10%  rosettes with 
K562 cells. 
~; Performed with AB serum from an individual containing anti-Rh antibodies. 
TABLE  II 
Inhibition  of the Interaction  between the Anti-Gal IgG and Rabbit RBC, by Various 
Carbohydrates 
Test substance 
Rosette formation 
Percentage of  Carbohydrate  Inhibition of 
rosettes at 100  concentration in-  RabRBC agglu- 
mM carbohy-  hibiting 50% ro-  tination* 
drate  sette formation 
%  mM  mM 
Control  100  --  -- 
D-Galactose  0  2  6 
D-Glucose  85  --  -- 
D-Fructose  95  --  -- 
D-Fucose  10  12  25 
L-Fucose  100  --  -- 
o-Mannose  100  --  -- 
a-Methyl-galactoside  0  0.7  1.5 
fl-Methyl-galactoside  10  25  50 
a-Methyl-glucoside  100  --  -- 
N-Acetyl-D-galactosamine  95  --  -- 
N-Acetyl-~glucosamine  95  --  -- 
fl-Galactosyl-glucoside (lactose)  85  --  -- 
a-Galactosyl-glucoside (melibiose)  0  0.7  1.5 
Sucrose  100  --  -- 
fl-Galactosyl-thiogalactoside  100  --  -- 
fl-Galactosyl-arabinoside  80  --  -- 
a-Galactosyl-a-galactosyl-a-glucosyl-fl-  0  1.5  3 
fructose (stachyose) 
* The assay was carried out in anti-Gal concentration yielding two agglutination units. GALILI  ET  AL.  1523 
the specific rabbit anti-human  IgG serum. A  Mancini radial  immunodiffusion 
assay with the isolated antibody indicated that the antibody concentration within 
the serum ranged from 30 to 70 #g/ml. Isoelectric focusing followed by immune 
fixation with anti-IgG antibodies showed the isolated anti-Gal to be a polyclonal 
antibody with pI values ranging from 4.0 to 8.5. 
The  specific  interaction  of the  anti2Gal  with  a-galactosyl  residues  on  the 
RabRBC was shown by the rosetting antiglobulin test as well as by hemaggluti- 
nation (Table II). Galactose at a concentration of 100 mM completely inhibited 
binding of the anti-Gal to the RabRBC and formation of rosettes, whereas 50% 
rosette inhibition  was observed by a  galactose concentration as low as 2  raM. 
Agglutination of the RabRBC by the antibody was noted at a galactose concen- 
tration not higher than 6 mM. The a-galactosyl-containing carbohydrates meli- 
biose, stachyose, and a-methyl-galactoside inhibited the anti-Gal reactivity more 
potently than did galactose. In contrast,/3-galactosyl-containing disaccharides did 
not affect the binding even at  100 mM. Accordingly,/3-methyl-galactoside was 
30-fold less effective than a-methyl-galactoside in inhibiting anti-Gal reactivity. 
Other carbohydrates tested, with the exception of o-fucose, failed to inhibit 
the binding of the anti-Gal to RabRBC  even at the concentration of 100 mM. 
The capacity of D-fucose to partially inhibit the anti-Gal reactivity is probably 
due to the identical arrangement of hydrogen and hydroxyl groups at positions 
C-2, C-3, and C-4 as in D-galactose. 
Binding  of Anti-Gal  to Human RBC.  Since anti-Gal is present in high titers in 
normal sera, it is not surprising that the antibody does not bind to freshly isolated 
human RBC (Table III). Proteolytic treatment of human RBC by 0.1% pronase 
for 60 min at 37°C resulted in extensive binding of the anti-Gal, as indicated by 
the high proportion of rosettes obtained after incubation of treated RBC with 
the antibody. This interaction was readily inhibited by galactose and a-galactosyl- 
containing carbohydrates, but not by B-galactosyl-containing  carbohydrates, fruc- 
tose, glucose, or mannose (not shown). Furthermore, incubation of the pronase- 
TABLE  III 
anti-Gal Binding by Various Human RBC Populations 
RBC source  Enzymatic treatment  Percentage of 
rosettes 
1.  Normal RBC 
2.  Normal RBC 
3.  Normal RBC 
4.  Normal RBC 
5.  Normal young RBC* (density <1.08 g/ 
ml) 
6.  Normal senescent RBC* (density >1.11  None 
g/ml) 
7.  Thalassemic RBC  None 
None 
Pronase 
Pronase followed by a- 
galactosidase 
Pronase followed by/~- 
galactosidase 
None 
% 
3 +  0.6* 
100 
74"1.3 
100 
5_+  1.5 
56 +  7.6 
72 _+ 8.3 
* Mean 4- SE of results obtained with the RBC of 8-10 individuals of 0 blood group, after incubation 
with purified anti-Gal isolated from AB serum. 
* Rosetting antiglobulin test performed with VCN-treated K562 cells. 1524  NATURAL  ANTIGALACTOSYL  lgG  IN  HUMAN  SERUM 
FmURE  1.  Demonstration in scanning electron microscope of the binding of Staphylococcus 
aureus-sensitized  with anti-Gal IgG to various RBC. (a) Rabbit RBC (RabRBC). x  6,000.  (b) 
Thalassemic RBC. x  6,600. Note the surface deformation of this pathologically aged RBC. (c) 
Human  normal  senescent  RBC,  with  density  of  1.11  g/ml,  obtained  from  Perco|l density 
gradient, x  9,500. GALILI ET  AL.  1525 
FIGURE  l  c 
treated RBC with a-galactosidase eliminated the capacity of these RBC to interact 
with  the  anti-Gal,  whereas  incubation  with  /3-galactosidase  did  not  affect  the 
capacity to bind the antibody. As expected, the anti-Gal was devoid of antibodies 
binding to the/3-galactosyl units penultimate to terminal sialic acid residues, since 
the  isolated  antibody  was  adsorbed  on  VCN-treated  RBC  (see  Materials  and 
Methods).  Accordingly,  no  antibody binding  was detected after  incubation  of 
VCN-treated RBC with the anti-Gal. 
In addition to binding to RabRBC- and pronase-treated human RBC, the anti- 
Gal bound to thalassemic  RBC, which are known to be prematurely aged RBC 
(11). The binding, as assessed by the rosetting antiglobulin test (Table III), could 
be visualized in scanning electron microscopy using Staph A-sensitized with anti- 
Gal (Fig.  1 b).  In a previous study we have reported that thalassemic  RBC bind 
in situ IgG antibodies with anti-galactosyl specificity (12). Thus, the thalassemic 
RBC were incubated with 0.1  M  galactose for 60 min at 37°C, for the elution 
of the autologous antibodies. After this incubation, thalassemic  RBC formed 5- 
15%  rosettes  with  K562  cells,  whereas  the  binding  of the  natural  anti-Gal  to 
these RBC resulted in 55-100% rosette formation.  In accordance,  the Staph A 
sensitized with the anti-Gal readily bound to these deformed pathological  RBC 
(Fig.  1 b). Nonsensitized Staph A did not bind to thalassemic RBC. In extension 
of this finding, experiments have shown that there is specific binding of anti-Gal 
to normal  senescent,  but not  young,  RBC (Table  III,  Fig.  1 c).  To detect  the 
relatively small amount of anti-Gal  molecules bound to normal  senescent RBC, 
the K562 cells were pretreated with 0.04 U/ml of VCN. The VCN cleaved the 
sialic acid units from the K562 cells and diminished  the zeta potential  between 
the myeloid cell and the RBC. Thus, the affinity of the Fc portion of the RBC- 
bound IgG molecule for the Fc receptor on the K562 cell was increased. While 1526  NATURAL  ANTIGALACTOSYL  IgG  IN  HUMAN  SERUM 
half  of K562  cells  formed  rosettes  with  the  senescent  RBC  following  their 
incubation with anti-Gal, only a few rosettes were detected with the young RBC. 
Anti-Gal in Normal Sera of  Donors of Various Age Groups.  The titer of anti-Gal 
was assessed  in  the  sera  of 300  individuals  of varying ages.  In  >95%  of the 
normal  adult  population,  anti-Gal  titers  ranged  between  1:800  and  1:1,600 
irrespective of the blood group (Fig. 2). The anti-Gal, like other IgG antibodies, 
cross the placenta and were detected in cord blood in titers only slightly lower 
than those found in the maternal blood (Fig. 2). The anti-Gal titer decreases to 
its lowest level at the age of 3-6 mo, correlating with the decrease in the total 
IgG  level  at  this  age.  The  antibody  titer  was  found  to  increase  gradually 
thereafter, reaching the adult level by the age of 2-4 yr. The anti-Gal titer in 20 
elderly individuals (70-90 yr), was found to be within the same range as that of 
young adults. The binding of nonpurifed anti-Gal  to RabRBC in titer yielding 
100%  rosettes was inhibited  by D-galactose- and  a-galactosyl-containing  carbo- 
hydrates,  to  the  same  extent  as  the  inhibition  observed  using  the  purified 
antibody. Other carbohydrates, including ¢~-galactosyl-containing disaccharides, 
failed to affect this interaction (not shown). 
Anti-Gal Reactivity in Immunodeficient Individuals.  The ubiquitous presence of 
anti-Gal in high titers throughout life implies a constant antigenic stimulation.  It 
was thus assumed that the titration of anti-Gal may serve as a  useful method for 
the assessment of humoral immunodeficiency disorders. The serum of an infant 
with  Bruton  type  agammaglobulinemia  contained  only  20%  of the  anti-Gal 
reactivity observed in  the  serum  of an  age-matched  healthy  individual  (Table 
IV).  A  similar difference was observed in  the serum  IgG concentration  of the 
two infants.  After administration  of a y-globulin preparation  to the immunode- 
ficient patient,  a  10-fold increase in  the anti-Gai  titer  was observed.  Reduced 
activity of the anti-Gal was similarly found in acquired immunodeficiencies. The 
100, 
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FIGURE 2.  Anti-Gal  reactivity  in  normal  sera  of  various  age  groups,  as  assayed  by  the 
interaction with RabRBC in the rosetting antiglobulin test. Dotted area, anti-Gal reactivity in 
290 out of 300 normal sera of all blood types. This group of serum donors included 20 elder 
individuals (70-90 yr old) and 30 youngsters (3-10 yr old). Closed circles, cord blood sera of 
30 individuals (mean +  SE).  Opened circles, sera of the 3-6-mo-old children (20 individuals, 
mean +  SE). GALILI  ET  AL. 
TABLE  IV 
Anti-Gal Titers in the Sera of lmmunodeficient  Patients 
1527 
Disease 
Patients  Age-matched 
controls 
Anti-Gal  Anti-Gal 
Age  titer  IgG  titer  IgG 
rag/ral  rag/ral 
1.  Bruton type agammaglobuline-  4 mo  1:10  0.4  1:50  2.2 
mia* 
After administration of 10 ml  1:100  3.8 
3,-globulin preparation 
2.  Multiple myeloma*  65 yr  1:10  45.0  1:800  12.0 
3.  Chronic lymphocytic leukemia*  70 yr  1:25  0.7  1:800  12.0 
(10  s lymphocytes/mm  3 
blood) 
* Diagnosis was made due to the absence of B lymphocytes in the blood and the complete lack of 
IgM and IgA antibodies in the serum. 
A representative case from a group of five patients where similar results were obtained. 
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FIGURE 3.  Anti-Oal reactivity in the serum of a 6-yr-old patient receiving 40 mg/d prednis- 
olone as immunosuppressive regimen. Anti-Gal reactivity at ((3) day zero; (rq) 30 d of treatment; 
(A) 60 d, and (V) 75 d. 
sera of the multiple myeloma patients tested, contained four- to fivefold increase 
in the serum IgG concentration, however, anti-Gal titers were 40-80-fold lower 
than that in normal sera. This is due to the abnormal clone of IgG comprising 
most of the serum immunoglobulin entity. Advanced chronic lymphocytic leu- 
kemia is another type of secondary immunodeficiency state where most of the 
antibody-producing lymphoid tissue is replaced by the malignant lymphocytes. 
Accordingly, anti-Gal titer was found to be very low. 
Active immune suppression caused by glucocorticoid treatment was similarly 
reflected in  the  titer  of anti-Gal,  as  seen  in  the  serum  of a  6-yr-old patient 
suffering from hemophagocytic lymphohistiocytosis, receiving a daily dose of 40 
mg prednisolone for the suppression of antibody production. It should be noted 
that a decrease of anti-Gal reactivity to 1:400 titer was observed only after 30 d 
of treatment, whereas additional 30 d  of administration resulted in the further 
decrease of anti-Gal titer to 1:100 (Fig. 3). Prednisolone administration for 75 d 1528  NATURAL  ANTIGALACTOSYL  IgG  IN  HUMAN  SERUM 
resulted in a decrease of the anti-Gal titer to  1:50. This titer did not alter upon 
continuation of the immunosuppressive treatment for additional 45 d. 
Discussion 
The natural anti-Gal IgG that is described in the present study seems to be the 
same antibody previously described by us to be present in situ  on thalassemic 
RBC (12).  In that study we isolated the antibody through binding to RabRBC 
and elution by galactose. In the present study, we demonstrate the isolation of 
the antibody by affinity chromatography with a chemically defined antigen and 
show the distinct anti-a-galactosyl specificity of the antibody. The anti-Gal differs 
from all  human natural antibodies with known anti-galactosyl specificity. The 
anti-blood group B antibody, which also displays an anti-a-galactosyl specificity, 
is present only in A  type and 0  type individuals and is mostly of the IgM class 
(2).  The anti-Gal  is present in  sera of all  blood  groups and is  mainly an  IgG 
antibody, as indicated by the almost similar titers observed in maternal and fetal 
blood. IgM antibodies do not cross the placenta. The anti-Gal differs from the 
anti-T antibody, which is mostly of the IgM class and interacts specifically with 
fl-D-Gal(l  --~  4)GlcNAc  residues naturally  present  on  cortical  thymocytes or 
exposed on other cell types after VCN treatment for removal of terminal sialic 
acid units (3,  13,  14).  It should be stressed that, unlike anti-T antibodies, which 
are  found in  the  serum of all  mammals tested  (3),  the anti-Gal  reactivity as 
assessed by its binding  to  RabRBC  could be demonstrated only in  human or 
baboon serum, but not in the serum of mice, rats, guinea pigs, and rabbits. From 
the structural components known to be present on RabRBC, it is most likely that 
the anti-Gal binds to the glycosphingolipid Galot(1 ~  3)Gal/3(1 ~  3)GIcNAc/3(1 
3)GalB(1  ~  4)Glc-O-ceramide, which is found to be present on these RBC 
(6). The assumption that anti-Gal binds to glycolipids on RabRBC, while not yet 
proven, is supported by the finding that pronase-treated RabRBC bind the anti- 
Gal  four-  to  eightfold  more than  do  nontreated  RabRBC  (not  shown).  It  is 
possible that the IgM moiety of the anti-Gal, which was not investigated in the 
present study, may reflect the heterophilic antibodies to RabRBC described long 
ago by Schiff (15) to be present in normal human sera. 
The specific binding of anti-Gal to normal and pathologically senescent RBC 
may imply a physiological role for this antibody in the aging of human RBC. In 
situ binding of autologous IgG to normal senescent RBC has been reported (10, 
16). 
The  observed  selective in  vitro  binding  of the isolated  natural  anti-Gal  to 
senescent but  not young RBC  possibly reflects an  in  vivo mechanism for the 
labeling of the aging RBC to be recognized by the macrophages of the reticu- 
loendothelial system. 
The binding site of anti-Gal on human RBC is still under study. The extensive 
binding  of the  anti-Gal  to  pronase-treated  RBC  suggests  that  the  antibody 
interacts with a  glycolipid rather than a  glycoprotein. The elimination of the 
antibody binding as a result of treatment with ot-galactosidase further implies the 
a-galactosyl structure on the binding epitope. The only kown glycolipid to be 
present on  all  human  RBC  and  to  bear  terminal a-galactosyl residues is  the 
trihexose ceramide molecule Gala(1 ~  4)Gal/3(1 ~  4)Glc-O-ceramide (17), which GALILI ET AL.  1529 
is  related  to  pk  antigen  (18).  The  possibility  that  trihexose  ceramide is  the 
antigenic determinant, which in course of senescence becomes accessible to anti- 
Gal binding through the removal of membranal proteins (including those bearing 
sialic acid), is currently under investigation. 
The anti-Gal was found to be present in sera of individuals above the age of 4 
yr in  a  remarkably high titer ranging between  1:800  and  1:1600.  A  marked 
decrease in  the  anti-Gal  titer  was  found  only in  infants  of 3-6  mo.  This  is 
compatible with the total decrease of maternal IgG and the initiation of self IgG 
synthesis. The unaltered production of the antibody throughout life implies a 
constant antigenic stimulation which, as in the anti-blood group antibodies, may 
originate in the intestinal flora (1).  E.  coli as well as shigella were reported to 
bear a-galactosyl groups on the cell wall (19) and thus may be the source of such 
antigenic stimulation.  Mixed agglutination experiments between the anti-Gal- 
sensitized Staph A  and various intestinal bacterial strains may help to establish 
this issue. 
The  observed  invariable  high  titer  of the  anti-Gal  may have  a  diagnostic 
significance in  providing information on the general function of the humoral 
immune system. This is demonstrated by the finding that primary and secondary 
humoral immune deficiencies, as well as active immune suppression, are reflected 
in the anti-Gal titer of the individual patient. The assessment of  immune reactivity 
by determination of the anti-Gal titer has the advantage over the commonly used 
titration of anti-blood group antibodies, since it is present in all individuals. In 
addition, blood group antibodies decrease with age (20). 
Further investigation of the natural anti-Gal antibody may not only provide 
clues to  the  mechanism of senescence of RBC,  but  may also  prove  that  this 
antibody takes part in the nonspecific amplification of local immune responses, 
since the trihexose ceramides are lipids present in membranes of a large amount 
of cells including fibroblasts (17), epithelial and kidney cells (21, 22). These cells, 
which normally are not exposed to serum antibodies due to physiological barriers, 
may be  found  to  bind  the  antibody  following  local  inflammatory reactions 
resulting from primary specific immune reactions. 
Additional study of this unique human natural IgG antibody may thus prove 
to be of immunological theoretical as well as practical interest. 
Summary 
A new natural anti-a-galactosyl IgG antibody (anti-Gal) was found to be present 
in high titer in the serum of every normal individual studied. The antibody was 
isolated  by  affinity  chromatography  on  a  melibiose-Sepharose  column.  The 
reactivity of the antibody was assessed by its interaction with a-galactosyl residues 
on rabbit erythrocytes (RabRBC).  The specificity was determined by inhibition 
experiments with various carbohydrates. The anti-Gal interacts with a-galactosyi 
residues,  possibly  on  glycolipids of human  RBC  (HuRBC),  after  removal  of 
membrane proteins by treatment with pronase.  In addition,  the anti-Gal bind 
specifically to normal and pathologically senescent HuRBC,  suggesting a  phys- 
iological  role  for this  natural  antibody in  the aging of RBC.  The  ubiquitous 
presence of anti-Gal in high titers throughout life implies a  constant antigenic 
stimulation. In addition to the theoretical interest in the antibody, the study of 1530  NATURAL  ANTIGALACTOSYL IgG  IN  HUMAN  SERUM 
the anti-Gal reactivity seems to bear immunodiagnostic significance. Decrease in 
the antibody titer was found to reflect humoral immunodeficiency disorders. 
The helpful suggestions of Dr. E. A. Kabat are gratefully acknowledged. 
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